Download the free e-book on peptides, hormones and pharmaceuticals for longevity, health and performance here: get the e-book
The conversation around GLP-1 receptor agonists has been dominated by injectable formulations since the class first demonstrated its transformative metabolic effects. The weekly subcutaneous injection has been the standard delivery method for semaglutide, tirzepatide, and the compounds that followed them, and for most people in supervised protocols it has become routine enough that the injection itself is not a meaningful barrier.
But it is a barrier for some people. And the development of oral GLP-1 formulations, available both as commercially manufactured products and through compounding pharmacy preparations, opens the class to a population that would not or could not use injectable compounds while also offering a different pharmacokinetic profile that has its own clinical implications.
Understanding what actually changes when GLP-1 compounds are delivered orally, what stays the same, and who the oral formulations are most appropriate for, is the subject of this article.
The bioavailability challenge
The fundamental challenge with oral delivery of peptide-based compounds is the gastrointestinal environment. The stomach and small intestine are designed to break down proteins and peptides into their component amino acids for absorption. A peptide compound swallowed in a capsule or tablet faces immediate degradation by gastric acid and digestive enzymes before it can reach systemic circulation in meaningful concentrations.
This is why most peptide compounds are administered by injection. Subcutaneous injection bypasses the digestive environment entirely, allowing the compound to enter systemic circulation without degradation and produce reliable plasma concentrations.
GLP-1 receptor agonists present this challenge acutely because they are peptide-based compounds that are particularly susceptible to gastrointestinal degradation. The commercial solution for semaglutide, which is the only GLP-1 receptor agonist with an FDA-approved oral formulation, Rybelsus, was to combine the active compound with a permeation enhancer called sodium salcaprozate, or SNAC, that temporarily increases absorption in the gastric lining before the compound can be degraded. This produces sufficient bioavailability for therapeutic effect but at the cost of requiring very specific administration conditions to work.
How oral semaglutide works differently from injectable
The pharmacokinetic profile of oral semaglutide is meaningfully different from injectable semaglutide in ways that have clinical implications.
Injectable semaglutide, administered once weekly, produces a gradual rise to peak plasma concentration over several days followed by a slow decline over the remainder of the week. This relatively flat pharmacokinetic curve means that plasma concentrations are reasonably stable throughout the week, providing consistent receptor engagement and consistent appetite suppression.
Oral semaglutide taken daily produces a much sharper peak shortly after administration followed by a rapid decline over several hours. The daily dosing frequency compensates partially for this shorter duration of action, but the resulting plasma concentration profile is more variable than injectable, with peaks and troughs that can produce more variable appetite suppression throughout the day compared to the relative consistency of the weekly injectable.
The absorption of oral semaglutide is also highly sensitive to administration conditions. It must be taken on an empty stomach with a small amount of water only, at least 30 minutes before any food, drink other than water, or other medications. Deviating from these conditions significantly reduces absorption. For people who have difficulty maintaining this regimen consistently, the effective dose they are receiving may be substantially lower than intended.
Compounded oral GLP-1 formulations
Beyond the FDA-approved Rybelsus, compounding pharmacies have developed oral tablet and capsule formulations of semaglutide and tirzepatide that are available through the platform catalogue.
The compounded oral formulations use similar approaches to the commercial product to improve gastrointestinal stability and absorption, though the specific formulation details vary by pharmacy. EPIQ's oral semaglutide and tirzepatide tablets, available in multiple dose strengths, represent the catalogue's primary offering in this category.
The compounded oral formulations offer several practical advantages. They are more accessible for people who are strongly averse to self-injection. They remove the need for needles, syringes, and the associated sharps disposal. And for some people the daily oral routine feels more manageable than a weekly injection, even though the injection itself is objectively a simpler and more reliable delivery method from a pharmacokinetic standpoint.
The trade-offs are real. Oral bioavailability is lower and more variable than injectable. The administration requirements for optimal absorption add a behavioral requirement that injectable compounds do not have. And the dose equivalency between oral and injectable formulations is not straightforward, meaning that transitioning between delivery methods requires clinical guidance rather than simple conversion.
Who oral formulations are most appropriate for
The clinical profile of the ideal oral GLP-1 candidate differs in some meaningful ways from the injectable candidate, though the metabolic goals and biological mechanisms are the same.
Injection aversion is the most straightforward indication. For people who have a genuine and significant aversion to self-injection that represents a real barrier to accessing injectable GLP-1 therapy, oral formulations provide an alternative that preserves access to the compound class. Some people will simply not self-inject regardless of how beneficial the therapy is, and oral access is meaningfully better than no access.
For people who are earlier in their metabolic optimization journey and whose goals are more modest, the somewhat lower and more variable efficacy of oral formulations may be sufficient. Someone seeking a 10 to 12 percent reduction in body fat over a longer timeline may achieve their goal with oral formulations even if the same person would achieve better results with injectable.
For people who are already achieving their goals with oral formulations and for whom the simplicity and convenience of daily oral dosing outweighs the pharmacokinetic advantages of injectable, there is no clinical reason to switch to injectable if the current approach is working.
What does not change with oral delivery
The mechanism is identical regardless of delivery route. When semaglutide or tirzepatide reaches GLP-1 receptors, it produces the same receptor activation, the same downstream signaling, and the same biological effects whether it arrived there via subcutaneous injection or oral absorption. The appetite suppression, improved satiety signaling, slowed gastric emptying, blood sugar regulation, and metabolic improvements that characterize the class are all driven by the same receptor mechanism.
The side effect profile is also broadly similar between oral and injectable formulations. The gastrointestinal effects, nausea, vomiting, diarrhea, and constipation that are the most common adverse effects with GLP-1 therapy, occur with oral formulations as well. Some people find gastrointestinal side effects more pronounced with oral formulations given the local gastrointestinal exposure of the compound during absorption, while others find them similar or less pronounced than injectable. Individual experience varies considerably.
The requirement for physician oversight, appropriate candidate selection, and gradual dose titration applies equally to oral and injectable formulations. The compound class, its benefits, and its risks are the same regardless of delivery method.
The tirzepatide oral question
Tirzepatide's oral formulation through compounding is a more recent development than oral semaglutide, and the evidence base for oral tirzepatide specifically is more limited. Eli Lilly, the manufacturer of injectable tirzepatide, is developing an oral tirzepatide formulation in clinical trials, but it is not yet commercially approved.
The compounded oral tirzepatide available through the catalogue draws on the same formulation approaches used for oral semaglutide, applied to the tirzepatide molecule. The dual GLP-1 and GIP mechanism is preserved in oral delivery, as is the case with semaglutide, though the same bioavailability and consistency considerations that apply to oral semaglutide apply here as well.
For people who specifically want tirzepatide's dual mechanism and cannot or will not use injectable, compounded oral tirzepatide provides access to the compound. For people who are flexible on mechanism and primarily want to avoid injection, oral semaglutide with its more established oral formulation track record may be the more straightforward choice.
The practical decision framework
The decision between oral and injectable GLP-1 formulations comes down to a relatively clear set of considerations.
If injection is not a barrier and efficacy is the primary concern, injectable formulations produce more reliable plasma concentrations, more consistent appetite suppression, and in head-to-head comparisons with oral formulations have generally shown greater weight loss outcomes for equivalent active compound doses.
If injection is a genuine barrier and access to the compound class is the primary concern, oral formulations provide that access with a mechanism that is identical even if the delivery efficiency is lower.
If someone has tried injectable formulations and experienced tolerability issues, oral formulations are not a reliable alternative on the basis that lower absorption will reduce side effects, because the same gastrointestinal side effects occur through both routes.
If someone is currently achieving their goals with oral formulations and values the simplicity of daily oral dosing, there is no clinical reason to change what is working.
The right choice is the one that the individual will actually use consistently, under appropriate physician supervision, with realistic expectations about what each delivery method produces.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making any changes to your health regimen. For more information visit www.peakformrx.health